In the latest session, Intra-Cellular Therapies Inc. (NASDAQ: ITCI) closed at $53.91 down -2.04% from its previous closing price of $55.03. In other words, the price has decreased by -$1.12 from its previous closing price. On the day, 739096 shares were traded. ITCI stock price reached its highest trading level at $54.82 during the session, while it also had its lowest trading level at $52.75.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Ratios:
For a deeper understanding of Intra-Cellular Therapies Inc.’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.10 and its Current Ratio is at 7.60. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on April 20, 2023, initiated with a Overweight rating and assigned the stock a target price of $80.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 07 when Neumann Mark sold 55,300 shares for $58.79 per share. The transaction valued at 3,251,087 led to the insider holds 45,339 shares of the business.
Durgam Suresh K. sold 1,842 shares of ITCI for $119,730 on Jul 17. The EVP, Chief Medical Officer now owns 21,262 shares after completing the transaction at $65.00 per share. On Jun 14, another insider, Hineline Lawrence J., who serves as the SVP of Finance CFO of the company, sold 81,854 shares for $63.97 each. As a result, the insider received 5,236,329 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ITCI now has a Market Capitalization of 5.18B and an Enterprise Value of 4.69B. For the stock, the TTM Price-to-Sale (P/S) ratio is 14.51 while its Price-to-Book (P/B) ratio in mrq is 8.52. Its current Enterprise Value per Revenue stands at 15.16 whereas that against EBITDA is -19.63.
Stock Price History:
Over the past 52 weeks, ITCI has reached a high of $67.05, while it has fallen to a 52-week low of $42.01. The 50-Day Moving Average of the stock is 58.69, while the 200-Day Moving Average is calculated to be 56.01.
Shares Statistics:
For the past three months, ITCI has traded an average of 641.37K shares per day and 645.34k over the past ten days. A total of 95.95M shares are outstanding, with a floating share count of 93.47M. Insiders hold about 0.10% of the company’s shares, while institutions hold 94.50% stake in the company. Shares short for ITCI as of Aug 30, 2023 were 2.55M with a Short Ratio of 2.55M, compared to 2.03M on Jul 30, 2023. Therefore, it implies a Short% of Shares Outstanding of 2.66% and a Short% of Float of 3.08%.
Earnings Estimates
There are 12 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.55 for the current quarter, with a high estimate of -$0.45 and a low estimate of -$0.67, while EPS last year was -$0.57. The consensus estimate for the next quarter is -$0.59, with high estimates of -$0.46 and low estimates of -$0.78.
Analysts are recommending an EPS of between -$1.88 and -$2.38 for the fiscal current year, implying an average EPS of -$2.07. EPS for the following year is -$0.69, with 11 analysts recommending between $0.1 and -$1.54.
Revenue Estimates
A total of 11 analysts believe the company’s revenue will be $119.68M this quarter.It ranges from a high estimate of $124.78M to a low estimate of $115.6M. As of the current estimate, Intra-Cellular Therapies Inc.’s year-ago sales were $66M, an estimated increase of 81.30% from the year-ago figure. For the next quarter, 11 analysts are estimating revenue of $135.12M, an increase of 53.80% less than the figure of $81.30% in the same quarter last year. There is a high estimate of $145.3M for the next quarter, whereas the lowest estimate is $129.9M.
A total of 12 analysts have provided revenue estimates for ITCI’s current fiscal year. The highest revenue estimate was $468.82M, while the lowest revenue estimate was $454.2M, resulting in an average revenue estimate of $460.41M. In the same quarter a year ago, actual revenue was $250.31M, up 83.90% from the average estimate. Based on 12 analysts’ estimates, the company’s revenue will be $671.79M in the next fiscal year. The high estimate is $760M and the low estimate is $608M. The average revenue growth estimate for next year is up 45.90% from the average revenue estimate for this year.